Treatment Opportunities for Colorectal Liver Metastases - European Medical Journal

Continue

Treatment Opportunities for Colorectal Liver Metastases

Hepatology
Download PDF
Author:
*Tormod Lund

Surgical Department, Vestre Viken Hospital Trust, Drammen, Norway.
*Correspondence to [email protected]

Disclosure:

The author has declared no conflicts of interest.

Received:
05.02.16
Accepted:
10.03.16
Citation:
EMJ. ;1[2]:76-83. DOI/10.33590/emj/10311794. https://doi.org/10.33590/emj/10311794.
Keywords:
Colorectal liver metastases (CLM), circulating tumour cells, immunotherapy, associating liver partition and portal vein ligation for staged hepatectomy (ALPPS), resection and partial liver segment II/III transplantation with delayed total hepatectomy (RAPID)

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Abstract

Colorectal liver metastases (CLM) are the most common hepatic malignancy and are caused by disseminated tumour cells (DTCs) seeded early in the tumourigenesis of colorectal cancer. Despite optimal treatment, CLM are associated with high mortality rates. This review provides an overview of three promising strategies to extend survival in CLM: treatment of DTCs, immunotherapy, and new surgical resection techniques.

Please view the full content in the pdf above.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.